| Bioactivity | LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR[1]. | |||||||||
| Invitro | LG100754 is a selective activator of endogenous RXR heterodimers[1].LG100754 can also improve TNFα-mediated insulin resistance in mature adipocytes[1].LG100754 acts as a bona fide activator of endogenous RXR:PPARγ heterodimers and regulator of insulin-dependent signaling pathways[1]. | |||||||||
| In Vivo | LG100754 (100 mg/kg) completely blocks the increase in glucose levels, suggesting that LG100754 can improve insulin resistance in vivo[1]. | |||||||||
| Name | LG100754 | |||||||||
| CAS | 180713-37-5 | |||||||||
| Formula | C26H36O3 | |||||||||
| Molar Mass | 396.56 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Cesario RM, et al. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9. |